[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351229-105":59,"doc-detail-351229-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","clinically-actionable-pharmacogenomic-variants-for-anticancer-therapy-in-nigeria-first-comprehensive-variant-profiling-in-underrepresented-nigerian-cohorts","Clinically actionable pharmacogenomic variants for anticancer therapy in Nigeria: first comprehensive variant profiling in underrepresented Nigerian cohorts","","Advances in pharmacogenomic research enable precision cancer care, yet Nigerian evidence on how pharmacogenomic variants affect anticancer drug efficacy and safety remains limited. This study profiles minor allele frequencies and genotype distributions of clinically validated pharmacogenomic variants in 207 Nigerian participants from the 1000 Genomes Project, comparing Yoruba and Esan groups with global references. Results reveal population-specific patterns across key genes, supporting pharmacogenetic screening to guide dose optimization and improve oncology outcomes.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinically-actionable-pharmacogenomic-variants-for-anticancer-therapy-in-nigeria-first-comprehensive-variant-profiling-in-underrepresented-nigerian-cohorts/351229/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinically-actionable-pharmacogenomic-variants-for-anticancer-therapy-in-nigeria-first-comprehensive-variant-profiling-in-underrepresented-nigerian-cohorts/351229.png","ImageObject",300,407,{"name":92,"@type":93},"Mia  ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main objective regarding pharmacogenomic variants in Nigeria?","Question",{"text":112,"@type":113},"To investigate minor allele frequencies and genotype distributions of all clinically validated pharmacogenomic variants linked to anticancer drugs in Nigerian populations.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which Nigerian cohorts were analyzed in this profiling study?",{"text":117,"@type":113},"The study included 207 Nigerians from the 1000 Genomes Project, with participants from the Yoruba (n=108) and Esan (n=99) tribes.",{"name":119,"@type":110,"acceptedAnswer":120},"What key findings were observed for CYP2D6 and tamoxifen metabolism?",{"text":121,"@type":113},"CYP2D6 poor metabolizer phenotypes marked by CYP2D6*4 were infrequent in Esan (1.0%) and absent in Yoruba, suggesting potential reduced tamoxifen efficacy.",{"name":123,"@type":110,"acceptedAnswer":124},"Why do the authors conclude pharmacogenetic screening is clinically important for Nigerian cancer care?",{"text":125,"@type":113},"Because the observed variant patterns are population-specific and can guide dose optimization, minimize adverse effects, and improve therapeutic outcomes through more effective precision medicine.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},351229,1790198277,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Ukpe and Ezeanuka BMC Medical Genomics (2026) 19:46 BMC Medical Genomics  \n[https://doi.org/10.1186/s12920-026-02324-7](https://doi.org/10.1186/s12920-026-02324-7)  \nRESEARCH Open Access  \nClinically actionable pharmacogenomic variants for anticancer therapy in Nigeria: first comprehensive variant profiling in underrepresented Nigerian cohorts  \nMichael Pius Ukpe1* and Anastecia Chinasa Ezeanuka 1  \nAbstract  \nBackground Advances in pharmacogenomic research have ushered in a new era of precision medicine in cancer care. However, evidence on the effects of pharmacogenomic variants on anticancer drug efficacy and safety in the Nigerian population is scarce. As a result, pharmacogenomic testing is not currently included in cancer care in Nigeria. This study aimed to investigate the minor allele frequencies (MAFs) and genotype distributions of all clinically validated pharmacogenomic variants associated with anticancer drugs in the Nigerian population at PharmGKB Level A1 . Methods Allele counts and allele frequencies of germline pharmacogenomic variants associated with cancer therapeutics obtained from the Clinical Pharmacogenetics (ClinPGx) database were retrieved from the Phase 3  \n1,000 Genomes project via the Ensembl REST API and genome browser. The primary population of interest in this study was the 207 Nigerians included in the 1000 Genomes Project (1KGP) (the Yoruba (n = 108) and Esan (n = 99) tribes) . The study included pharmacogenetic variants with Level 1 A evidence CYP2D6*4 (Tamoxifen), CYP3A5*3, *6,*7 (Tacrolimus), DPYD rs115232898, rs17376848, rs1801159, rs1801265 (5-Fluorouracil and Capecitabine), and TPMT*3C (Thiopurines: 6-MP, Azathioprine) . Hardy–Weinberg equilibrium (HWE) was calculated, and a cross-population comparative analysis was conducted between Nigerian populations and global reference populations from Europe (British), East Asia (Han Chinese), and the Americas (Peruvians) .  \nResults Among the Esan and Yoruba populations in Nigeria, CYP2D6 poor metabolizer phenotypes (defined by two non-functional diplotypes according to CPIC) were infrequent and observed for CYP2D6*4 at a frequency of 1. 0%(95% CI: 0 .2–5. 5) in the Esan population, while absent in the Yoruba population, with potential implications for reduced tamoxifen efficacy. Homozygosity for non-functional CYP3A5 alleles (*3, *6, and 7), indicating complete loss of CYP3A5 expression and corresponding to poor tacrolimus metabolizer status, was identified in approximately 3% of the Esan population and nearly twice that proportion in the Yoruba population. The minor allele frequency of DPYD rs115232898, associated with decreased fluorouracil metabolism, differed between populations, occurring at 1. 0%(95% CI: 0 .3–3. 6) in Esan and 4 . 2%(95% CI: 2 .2–7. 7) in Yoruba individuals. For TPMT*3C, non-functional diplotypes  \n*Correspondence:  \nMichael Pius Ukpe [scientistmichaelpius@gmail.com](scientistmichaelpius@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy o","cbCaieLfrE5yDw2e","https://ap.wps.com/l/cbCaieLfrE5yDw2e","pdf",1675980,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n## Keywords","[{\"question\":\"What was the study’s main objective regarding pharmacogenomic variants in Nigeria?\",\"answer\":\"To investigate minor allele frequencies and genotype distributions of all clinically validated pharmacogenomic variants linked to anticancer drugs in Nigerian populations.\"},{\"question\":\"Which Nigerian cohorts were analyzed in this profiling study?\",\"answer\":\"The study included 207 Nigerians from the 1000 Genomes Project, with participants from the Yoruba (n=108) and Esan (n=99) tribes.\"},{\"question\":\"What key findings were observed for CYP2D6 and tamoxifen metabolism?\",\"answer\":\"CYP2D6 poor metabolizer phenotypes marked by CYP2D6*4 were infrequent in Esan (1.0%) and absent in Yoruba, suggesting potential reduced tamoxifen efficacy.\"},{\"question\":\"Why do the authors conclude pharmacogenetic screening is clinically important for Nigerian cancer care?\",\"answer\":\"Because the observed variant patterns are population-specific and can guide dose optimization, minimize adverse effects, and improve therapeutic outcomes through more effective precision medicine.\"}]","Clinically actionable pharmacogenomic variants for anticancer therapy in Nigeria: first comprehensive variant profiling in underrepresented Nigerian cohorts | PDF",1790093135,23,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c24328bea2f81ce4e4e27daf34dfcce1.webp",983,1310,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2af4e1d12ba8775ee2f530ed0548f569.webp",982,1309,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a0faf1bf57c9abb53acc11166a5ebed.webp",981,1308,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/621ada21e649177b4518ecf95c3a0ba9.webp",980,1306]